Abstract 14435: Adipolin, a Novel Adipokine, is a Novel Cardioprotective Molecule in the Ischemic Rat Heart
Background: Adipolin is a novel adipokine with insulin sensitizing and anti-inflammatory effects of the C1q/TNF-Related Protein (CTRP) superfamily. Low circulating and adipose tissue Adipolin levels have been reported in rodent models of obesity and diabetes. To date, the impact of Adipolin on the cardiovascular system remains uncharted. We aimed to study the effect of full length Adipolin (fAdipolin) and globular Adipolin (gAdipolin) in an ischemic Langendorff perfused rat heart.
Methods: We assessed cardiac function and infarct size following global ischemia (30 minutes) and reperfusion (120 minutes), with or without fAdipolin or gAdipolin pre-treatment (0.25μg/ml/g/minute) in rats fed a standard chow diet (weight: 230 ± 10.8g) or a high fat diet (weight: 512 ± 18.9g).
Cardiac function: In an isolated rat heart Langendorff system, we measured left ventricular developed pressure (LVDP), relating to maximal rates of LV pressure decay and dP/dtmin and dP/dtmax (+/-dp/dt), a specific indicator of isovolumetric phase index of left ventricular contractility.
Infarct size: Infarct size was assessed by triphenyltetrazolium chloride staining and planimetry of the traced sections.
Results: The control (saline treated) exhibited poor cardiac functional recovery (Figure 1A), a significant decline in cardiac function (Figure 1B) and an increase in infarct size (Figure 2A) following global ischemia and reperfusion whence compared to pre-treatment with fAdipolin or gAdipolin fCTRP13. The cardioprotective effect of Adipolin was attenuated in obese rat hearts (Figure 1C & 2A).
Conclusions: Adipolin is a novel cardioprotective adipokine, the effects of which were decreased in obesity.
- © 2013 by American Heart Association, Inc.